A study on Acoramidis showed a notable decrease in the risk of cardiovascular mortality (CVM) over a 42-month period after randomization, achieving a 44% reduction in hazard. This sets a groundbreaking benchmark for CVM outcomes in individuals with ATTR-CM.
